Abstract
Objective
The etiology and pathogenesis of hyperemesis gravidarum (HG) is still undetermined and has been suggested to involve oxidative stress. We aimed to evaluate the status of oxidative stress in HG by measuring the levels of total oxidant status (TOS), total antioxidant status (TAS), and by calculating the oxidative stress index (OSI).
Methods
In a case–control trial, fasting morning blood samples of patients with HG (n = 41) and healthy pregnant women (n = 39) were collected for analysis of serum TOS and TAS values as well as for calculation of OSI according to the formula: OSI = TOS / TAS × 100.
Results
Serum TOS and TAS levels were similar in both groups. However, serum TAS levels were lower among HG patients compared to controls, which resulted in an increase in OSI (P = 0.025).
Discussion
The present study supports the role of systemic oxidative stress, reflected by an imbalance between the TOS and TAS, in patients with HG. Our findings distinguish the mechanism underlying oxidative stress to result from reduction of antioxidants rather than an increase in oxidants.
Keywords: Hyperemesis gravidarum, Oxidative stress index, Total antioxidant status, Total oxidant status
Introduction
Hyperemesis gravidarum (HG) is an uncommon disorder with intractable nausea and vomiting during the first trimester of pregnancy leading to fluid and nutritional deficiency, weight loss, electrolyte and acid–base imbalance, with an incidence of 0.3–1.5% of all pregnancies.1,2 This disorder may result in serious complications, including hepatic and renal impairment, Wernicke's encephalopathy, and even very rarely maternal or fetal death.3–7
The etiopathogenesis of HG is still unclear. To explain the etiology and pathophysiology of HG, there are hypotheses that include psychological, gastrointestinal, endocrinological, metabolic, infectious, immunological, and anatomical aspects.8,9
Oxidative stress can be described as an imbalance between oxidant substances (reactive oxygen species and antioxidant defenses) in living organisms. Oxidative stress has a role in various pathologic and physiologic conditions, including pregnancy and related complications.10,11
The relation between HG and oxidative stress has been evaluated previously but the results are conflicting.12–16 Previous studies reported that in the plasma of patients with pregnancy-related complications, superoxide dismutase, glutathione peroxidase, catalase activities, and non-enzymatic antioxidant levels are decreased, increased, or unchanged.17–20 Antioxidant activity has been shown to be statistically significantly higher in normal pregnancies compared to non-pregnant women. This augmented antioxidant activity was reported to continue to gradually increase throughout gestation.21,22 In normal pregnancies, an increased oxidative stress has been shown to be compensated by an increased antioxidant activity in serum.23
We aimed to evaluate the status of oxidative stress in HG patients by evaluating the levels of total oxidant status (TOS), total antioxidant status (TAS), and the oxidative stress index (OSI).
Materials and methods
Forty-one consecutive pregnant women with HG and 39 healthy pregnant women as a control group who met inclusion criteria and consented to be included in the study were enrolled in this case–control study between August and December 2013. The study was approved by the Institutional Review Board (10# 24/07/2013). This study was conducted according to the Declaration of Helsinki.24 Inclusion criteria were: gestational age between 6 and 14 weeks, singleton pregnancy, persistent nausea and vomiting (>4 times per day), ketonuria >80 mg/dl in a random urine specimen, and electrolyte imbalance that requires intravenous replacement. Exclusion criteria were: multiple pregnancy, known thyroid disease, trophoblastic disease, eating disorders, known psychiatric disorder, smokers, women taking medication or having inflammatory disorders such as urinary infection. None of the women in the study or the control population had any kind of restrictive diet (gluten and lactose intolerance or vegetarian diet) before or during pregnancy. All patients were hospitalized for at least 24 hours for treatment. The control group consisted of uncomplicated pregnant women admitted for antenatal care at the same gestational age (6–14 weeks) who were also matched for parity with the study group. Gestational age was determined by crown rump length measurement in the first trimester of pregnancy in cases where there were more than 3 days difference between ultrasonographic measurement and the last menstrual period. Body mass index was obtained by dividing body weight in kilograms by the square of height in meters.
Blood sample collection
Blood samples were taken after an overnight fast in the early morning. All samples were immediately stored on ice at 4°C before centrifugation within at most 2 hours after collection, as described by Verit et al.16 Centrifugation of the samples was performed at 4000 rpm for 10 minutes and the supernatant serum was separated and stored at −80°C until assay.
Measurement of TAS and TOS
Serum TAS and TOS levels were determined by the spectrophotometrical methods developed by Erel25,26 using commercial Rel Assay diagnostic kits (TAS lot no: RL030, TOS lot no: RL033, Gaziantep, Turkey). TAS had precision values lower than 3% and results were expressed as milimol Trolox Eq/l. TOS had precision values lower than 5% and results were expressed as micromol H2O2 Eq/l. Antioxidants in the sample reduced the dark blue-green-colored ABTS radical (2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)) to the colorless ABTS form. The difference in absorbance at 660 nm is associated with total antioxidant level. Calibration of the assay was performed with a stable antioxidant standard solution (traditional Trolox equivalent) with a vitamin E analog. Ferrous ion–chelator complex is oxidized to ferric ion by oxidants that are present in the sample. Enhancer molecules in the reaction medium prolong the oxidation reaction. In an acidic medium, the ferric ion generates a colored complex with chromogen. Measurement of the color intensity spectrophotometrically is associated with the total amount of oxidant molecules that are present in the sample. Lastly, the assay was calibrated with hydrogen peroxide and the results are denoted as micromolar hydrogen peroxide equivalent per liter (μmol H2O2 Eq/l)
Determination of OSI
OSI is a marker for the degree of oxidative stress as a combined ratio between pro-oxidants (TOS) and antioxidants (TAS). The OSI value was calculated by the formula: ‘OSI (arbitrary unit) = TOS (μmol H2O2 Eq/l)/TAS (mmol Trolox Eq/l) × 100’, as previously reported.27,28
Statistical analysis
Distribution of the data was analyzed with Kolmogorov–Smirnov and Shapiro–Wilk tests. The data are presented as mean with standard deviation or median with minimum and maximum values of ranges for continuous variables, and as number with percentage for categorical variables. Data with a normal distribution were analyzed using the independent samples test. The Mann–Whitney U test and median test were used to analyze non-normally distributed data. The Chi-square test was used to compare categorical variables. A two-tailed P value of less than 0.05 was considered statistically significant. SPSS 21.0 was used for statistical calculations (SPSS Inc., Chicago, IL, USA).
Results
There was no significant difference in terms of age, gravidity, parity, and gestational week between the patients with HG and the controls (Table 1). There was no statistically significant difference between groups in terms of serum hemoglobin, hematocrit, white blood cells, platelet, serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase (SGPT), urea, creatinine, and thyroid-stimulating hormone (TSH) levels (Table 2). Serum TOS and TAS levels were similar in both HG and control groups. The OSI in HG patients was significantly higher compared to the control group (P = 0.025) (Table 3 and Figs. 1 and 2).
Table 1.
Demographic data of the patients with HG and the control group
| Variables | HG§ (n = 41) | Control (n = 39) | P value |
|---|---|---|---|
| Age (years) | 28.8 ± 4.7 | 26.7 ± 6.3 | 0.133* |
| Gravidity | 3 (1–8) | 3 (1–9) | 0.563† |
| Parity | 1 (0–3) | 1 (0–4) | 0.947† |
| Gestational age (weeks) | 8.6 ± 2.0 | 8.7 ± 1.9 | 0.941* |
| Education status | 0.620‡ | ||
| Primary school | 16 (39%) | 18 (46.2%) | |
| High school | 16 (39%) | 16 (41%) | |
| College | 9 (22%) | 5 (12.8%) | |
| BMI¶ | 23.0 ± 3.5 | 24.8 ± 4.2 | 0.035* |
*Independent samples t-test.
†Mann–Whitney U test.
‡Chi-square.
§Hyperemesis gravidarum.
¶Body mass index.
Table 2.
Biochemical parameters of patients with HG and the control group
| Variables | HG† (n = 41) | Control (n = 39) | P value |
|---|---|---|---|
| Hemoglobin (g/dl) | 12.85 ± 1.0 | 12.49 ± 0.8 | 0.086* |
| Hematocrit (%) | 37.56 ± 2.5 | 36.56 ± 2.8 | 0.098* |
| White blood cell (×103/μl) | 9.67 ± 2.35 | 9.85 ± 2.05 | 0.727* |
| Platelet (×103/μl) | 256.56 ± 58.27 | 257.68 ± 50.71 | 0.929* |
| SGOT‡ (μ/l) | 17.65 ± 4.34 | 1745 ± 4.31 | 0.839* |
| SGPT§ (μ/l) | 19.16 ± 16.4 | 15.46 ± 13.2 | 0.279* |
| Urea (mg/dl) | 22.94 ± 5.6 | 21.11 ± 4.6 | 0.122* |
| Creatinine (mg/dl) | 0.53 ± 0.1 | 0.58 ± 0.1 | 0.073* |
| TSH¶ (μIU/ml) | 1.33 ± 1.6 | 1.68 ± 2.7 | 0.484* |
*Independent samples t-test.
†Hyperemesis gravidarum.
‡Serum glutamic oxaloacetic transaminase.
§Serum glutamic pyruvic transaminase.
¶Thyroid-stimulating hormone.
Table 3.
Total antioxidant status, total oxidant status, and oxidative stress index of HG patients and control groups
| HG† (n = 41) | Control (n = 39) | P value* | |
|---|---|---|---|
| TAS‡ (mmol Trolox Eq/l) (median and range) | 1.47 (0.32–2.75) | 1.90 (0.69–2.82) | 0.074 |
| TOS§ (μmol H2O2 Eq/l) (median and range) | 4.48 (3.39–8.12) | 4.48 (3.39–7.39) | 0.637 |
| OSI¶ (median and range) | 293.3 (136.7–1856.3) | 225.98 (150–702.9) | 0.025 |
*Median test.
†Hyperemesis gravidarum.
‡Total antioxidant status.
§Total oxidant status.
¶Oxidative stress index.
Figure 1.
Oxidative stress index and serum levels of TAS, TOS in the study group and control group.
Figure 2.
OSI and TAS values of HG and control patients.
To evaluate the potential effect of maternal-placental circulation and human chorionic gonadotropin (hCG), the data were analyzed according to the gestational week. In the group of 6–10 weeks of gestational age, the TAS levels were significantly lower and OSI levels were significantly higher than the control group. But these differences were not significant in the group of 11–14 weeks of gestational age (Table 4).
Table 4.
Total antioxidant status, total oxidant status, and oxidative stress index of HG patients and control groups at 6–10 weeks of gestation and 11–14 weeks of gestation
| 6–10 weeks of gestation | |||
|---|---|---|---|
| HG† (n = 33) | Control (n = 32) | P value* | |
| TAS‡ (mmol Trolox Eq/l) (median and range) | 1.30 (0.32–2.75) | 1.87 (0.69–2.82) | 0.024 |
| TOS§ (μmol H2O2 Eq/l) (median and range) | 4.48 (3.39–7.39) | 4.48 (3.39–7.39) | 0.594 |
| OSI¶ (median and range) | 326.2 (136.7–1856.3) | 232.4 (150–702.9) | 0.014 |
| 11–14 weeks of gestation | |||
| HG† (n = 8) | Control (n = 7) | P value* | |
| TAS‡ (mmol Trolox Eq/l) (median and range) | 2.26 (1.04–2.57) | 1.88 (0.73–2.62) | 0.536 |
| TOS§ (μmol H2O2 Eq/l) (median and range) | 4.06 (3.64–8.12) | 4.24 (3.52–4.85) | 1.000 |
| OSI¶ (median and range) | 248.6 (148–531.5) | 190.3 (152.9–454.8) | 0.336 |
*Mann–Whitney U test.
†Hyperemesis gravidarum.
‡Total antioxidant status.
§Total oxidant status.
¶Oxidative stress index.
Discussion
The present study provides evidence in favor of increased systemic oxidative stress among patients presenting with HG, resulting from an imbalance between the TOS and TAS. The evaluation of serum TAS, TOS, and OSI values was able to distinguish the elements separately involved in oxidative stress. So far, various oxidant and antioxidant compounds in patients with HG have been evaluated.12–16,29 Several laboratory kits with different methodology have been developed for the evaluation of oxidant reactive species, non-enzymatic molecules, and antioxidant enzymes.12–16,29
Overall, studies with different serum markers have identified alterations of oxidant and antioxidant status in HG, although some conflicting results have been reported.12–16 Serum levels of TAS and TOS were investigated in patients with nausea and vomiting in only one recent study.16 The investigators demonstrated that patients with HG had significantly higher TOS and lower antioxidant levels compared to controls. Likewise, we have found lower antioxidant levels, but no statistically significant difference was found between the study population and control group TAS levels. However, OSI was significantly different between the groups. When evaluating the conditions of oxidative stress, OSI is more unbiased and valuable compared to separate measurements of TAS and TOS since OSI shows the delicate balance between TAS and TOS more clearly.30 Low serum TAS levels and similar serum TOS levels in HG patients cause the pro-oxidant⁄antioxidant balance to shift toward the oxidant side and this results in oxidative stress.31 We conclude that this study presents more objective results than previous studies.12,15,16
There is limited information related to the effects of antioxidant defenses on early human development. However, as the fetus is prone to free-radical damage during the period when major organ systems are developing, antioxidant status is particularly important. Previous studies reported antioxidant activity to be significantly higher among normal pregnancies compared to non-pregnant conditions.21 Production of free radicals, which requires antioxidant activity to counteract it, has been shown to occur in normal placental tissues, where the enhanced antioxidant activity is needed to maintain a balance.13,32 It has been recently reported that oxidative stress plays a central role in the etiopathogenesis of RPL (Recurrent Pregnancy Loss).33 In the present study, although statistically insignificant, lower antioxidant activity compared to healthy pregnant women was observed among patients with HG, which is in accordance with other studies.3,16,34–36
Steroid hormones, especially hCG, secreted during early pregnancy, seem to be responsible for symptoms of HG. Patients with HG have been reported to have higher hCG levels compared to controls and HG incidence increases with higher hCG conditions such as multiple and molar pregnancies.37–40 In one study, Xing et al.41 found that oxidative stress stimulates the synthesis of different trophoblastic proteins, such as hCG and estrogens. In the present study, among the women at 6–10 weeks of gestational age, TAS levels were significantly lower in HG compared to the control group. After 11 weeks of gestation this difference was not present. Therefore, it can be speculated that increased oxidative stress in patients with HG at an early gestational age may be the reason for elevated hCG levels. On the other hand, starvation itself can also be the cause of oxidative stress. In other words, oxidative stress may be the result rather than the cause of HG.
Several theories have been proposed to explain the reason for decreased levels of antioxidants in HG. First, the decreased dietary intake of some nutrients rich in antioxidants is observed in women with HG.42 Second, expression of antioxidant enzymes is decreased in HG patients.15 Familial aggregation of HG may be related to genes associated with decreased antioxidant enzyme expression in patients with HG.43
In conclusion, systemic oxidative stress may have a significant role in the etiology and pathogenesis of HG. HG patients should be evaluated for other diseases associated with oxidative stress. In the present study, we found that oxidative stress in HG is associated with reduction of antioxidants rather than with an increase of oxidants. Our results emphasize the therapeutic potential of antioxidant supplementation, which is becoming an increasingly used approach in treating the symptoms of women with HG.
Disclaimer statements
Contributors Saynur YILMAZ; corresponding author, drafting the manuscript, conception and design of study. A. Seval OZGU-ERDINC; acquisition of data, drafting the manuscript, analysis and interpretation of data. Canan DEMIRTAS; acquisition of data. Gulfer OZTURK; acquisition of data. Salim ERKAYA; final approval of the version to be published. Dilek UYGUR; article drafting and revising it critically for important intellectual content.
Funding None.
Conflict of interest None.
Ethics approval The study was approved by the Institutional Review Board (10# 24/07/2013).
Acknowledgments
The authors wish to thank Peter Lemotte for revising the article as a native speaker.
References
- 1.Lee NM, Saha S. Nausea and vomiting of pregnancy. Gastroenterol Clin North Am 2011;40:309–34, vii. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Veenendaal MV, van Abeelen AF, Painter RC, van der Post JA, Roseboom TJ. Consequences of hyperemesis gravidarum for offspring: a systematic review and meta-analysis. BJOG 2011;118:1302–13. [DOI] [PubMed] [Google Scholar]
- 3.Chiossi G, Neri I, Cavazzuti M, Basso G, Facchinetti F. Hyperemesis gravidarum complicated by Wernicke encephalopathy: background, case report, and review of the literature. Obstet Gynecol Surv 2006;61:255–68. [DOI] [PubMed] [Google Scholar]
- 4.Di Gangi S, Gizzo S, Patrelli TS, Saccardi C, D'Antona D, Nardelli GB. Wernicke's encephalopathy complicating hyperemesis gravidarum: from the background to the present. J Matern Fetal Neonatal Med 2012;25:1499–504. [DOI] [PubMed] [Google Scholar]
- 5.Eliakim R, Abulafia O, Sherer DM. Hyperemesis gravidarum: a current review. Am J Perinatol 2000;17:207–18. [DOI] [PubMed] [Google Scholar]
- 6.Latham PS. Liver diseases. In: Gleicher N GS, Sibai BM, Elkayam U, Galbraith RM, Sarto GE, (eds.) Principles and practice of medical therapy in pregnancy. Upper Saddle River, NJ: Prentice Hall International, Inc; 1992. p. 960–9. [Google Scholar]
- 7.Ismail SK, Kenny L. Review on hyperemesis gravidarum. Best Pract Res Clin Gastroenterol 2007;21:755–69. [DOI] [PubMed] [Google Scholar]
- 8.Verberg MF, Gillott DJ, Al-Fardan N, Grudzinskas JG. Hyperemesis gravidarum, a literature review. Hum Reprod Update 2005;11:527–39. [DOI] [PubMed] [Google Scholar]
- 9.Quinla JD, Hill DA. Nausea and vomiting of pregnancy. Am Fam Physician 2003;68:121–8. [PubMed] [Google Scholar]
- 10.Wang YP, Walsh SW, Guo JD, Zhang JY. The imbalance between thromboxane and prostacyclin in preeclampsia is associated with an imbalance between lipid peroxides and vitamin E in maternal blood. Am J Obstet Gynecol 1991;165:1695–700. [DOI] [PubMed] [Google Scholar]
- 11.Biri A, Kavutcu M, Bozkurt N, Devrim E, Nurlu N, Durak I. Investigation of free radical scavenging enzyme activities and lipid peroxidation in human placental tissues with miscarriage. J Soc Gynecol Investig 2006;13:384–8. [DOI] [PubMed] [Google Scholar]
- 12.Onaran Y, Kafali H, Duvan CI, Keskin E, Celik H, Erel O. Relationship between oxidant and antioxidant activity in hyperemesis gravidarum. J Matern Fetal Neonatal Med. 2014 May;27(8):825–8. [DOI] [PubMed] [Google Scholar]
- 13.Fait V, Sela S, Ophir E, Khoury S, Nissimov J, Tkach M,. et al. Hyperemesis gravidarum is associated with oxidative stress. Am J Perinatol 2002;19:93–8 [DOI] [PubMed] [Google Scholar]
- 14.Aksoy H, Aksoy AN, Ozkan A, Polat H. Serum lipid profile, oxidative status, and paraoxonase 1 activity in hyperemesis gravidarum. J Clin Lab Anal 2009;23:105–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Guney M, Oral B, Mungan T. Serum lipid peroxidation and antioxidant potential levels in hyperemesis gravidarum. Am J Perinatol 2007;24:283–9. [DOI] [PubMed] [Google Scholar]
- 16.Verit FF, Erel O, Sav M, Celik N, Cadirci D. Oxidative stress is associated with clinical severity of nausea and vomiting of pregnancy. Am J Perinatol 2007;24:545–8. [DOI] [PubMed] [Google Scholar]
- 17.Maseki M, Nishigaki I, Hagihara M, Tomoda Y, Yagi K. Lipid peroxide levels and lipids content of serum lipoprotein fractions of pregnant subjects with or without pre-eclampsia. Clin Chim Acta 1981;115:155–61. [DOI] [PubMed] [Google Scholar]
- 18.Walsh SW, Wang Y. Deficient glutathione peroxidase activity in preeclampsia is associated with increased placental production of thromboxane and lipid peroxides. Am J Obstet Gynecol 1993;169:1456–61. [DOI] [PubMed] [Google Scholar]
- 19.Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol 2005;3:28. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Vidal ZE, Rufino SC, Tlaxcalteco EH,. et al. Oxidative stress increased in pregnant women with iodine deficiency. Biol Trace Elem Res 2014;157:211–7. [DOI] [PubMed] [Google Scholar]
- 21.Hubel CA, Roberts JM, Taylor RN, Musci TJ, Rogers GM, McLaughlin MK. Lipid peroxidation in pregnancy: new perspectives on preeclampsia. Am J Obstet Gynecol 1989;161:1025–34. [DOI] [PubMed] [Google Scholar]
- 22.Fait V, Sela S, Ophir E,. et al. Peripheral polymorphonuclear leukocyte priming contributes to oxidative stress in early pregnancy. J Soc Gynecol Investig 2005;12:46–9. [DOI] [PubMed] [Google Scholar]
- 23.Davidge ST, Hubel CA, Brayden RD, Capeless EC, McLaughlin MK. Sera antioxidant activity in uncomplicated and preeclamptic pregnancies. Obstet Gynecol 1992;79:897–901. [PubMed] [Google Scholar]
- 24.World Medical Association declaration of Helsinki Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925–6. [PubMed] [Google Scholar]
- 25.Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37:112–9. [DOI] [PubMed] [Google Scholar]
- 26.Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38:1103–11. [DOI] [PubMed] [Google Scholar]
- 27.Alp R, Selek S, Alp SI, Taskin A, Kocyigit A. Oxidative and antioxidative balance in patients of migraine. Eur Rev Med Pharmacol Sci 2010;14:877–82. [PubMed] [Google Scholar]
- 28.Karkucak M, Capkin E, Alver A,. et al. The effect of anti-TNF agent on oxidation status in patients with ankylosing spondylitis. Clin Rheumatol 2010;29:303–7. [DOI] [PubMed] [Google Scholar]
- 29.Verit FF, Erel O, Celik H. Paraoxonase-1 activity in patients with hyperemesis gravidarum. Redox Rep 2008;13:134–8. [DOI] [PubMed] [Google Scholar]
- 30.Esen C, Alkan BA, Kirnap M, Akgul O, Isikoglu S, Erel O. The effects of chronic periodontitis and rheumatoid arthritis on serum and gingival crevicular fluid total antioxidant/oxidant status and oxidative stress index. J Periodontol 2012;83:773–9. [DOI] [PubMed] [Google Scholar]
- 31.Yesilova Y, Ucmak D, Selek S,. et al. Oxidative stress index may play a key role in patients with pemphigus vulgaris. J Eur Acad Dermatol Venereol 2013;27:465–7. [DOI] [PubMed] [Google Scholar]
- 32.Perkins AV. Endogenous anti-oxidants in pregnancy and preeclampsia. Aust N Z J Obstet Gynaecol 2006;46:77–83. [DOI] [PubMed] [Google Scholar]
- 33.Yiyenoglu OB, Ugur MG, Ozcan HC,. et al. Assessment of oxidative stress markers in recurrent pregnancy loss: a prospective study. Arch Gynecol Obstet 2014;289:1337–40. [DOI] [PubMed] [Google Scholar]
- 34.van Stuijvenberg ME, Schabort I, Labadarios D, Nel JT. The nutritional status and treatment of patients with hyperemesis gravidarum. Am J Obstet Gynecol 1995;172:1585–91. [DOI] [PubMed] [Google Scholar]
- 35.Welsh A. Hyperemesis, gastrointestinal and liver disorders in pregnancy. Curr Obstet Gynaecol 2005;15:123–31. [Google Scholar]
- 36.Robinson JN, Banerjee R, Thiet MP. Coagulopathy secondary to vitamin K deficiency in hyperemesis gravidarum. Obstet Gynecol 1998;92:673–5. [DOI] [PubMed] [Google Scholar]
- 37.Fell DB, Dodds L, Joseph KS, Allen VM, Butler B. Risk factors for hyperemesis gravidarum requiring hospital admission during pregnancy. Obstet Gynecol 2006;107:277–84. [DOI] [PubMed] [Google Scholar]
- 38.Felemban AA, Bakri YN, Alkharif HA, Altuwaijri SM, Shalhoub J, Berkowitz RS. Complete molar pregnancy. Clinical trends at King Fahad Hospital, Riyadh, Kingdom of Saudi Arabia. J Reprod Med 1998;43:11–3. [PubMed] [Google Scholar]
- 39.Leylek OA, Toyaksi M, Erselcan T, Dokmetas S. Immunologic and biochemical factors in hyperemesis gravidarum with or without hyperthyroxinemia. Gynecol Obstet Invest 1999;47:229–34. [DOI] [PubMed] [Google Scholar]
- 40.Goodwin TM, Montoro M, Mestman JH, Pekary AE, Hershman JM. The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin Endocrinol Metab 1992;75:1333–7. [DOI] [PubMed] [Google Scholar]
- 41.Xing Y, Williams C, Campbell RK,. et al. Threading of a glycosylated protein loop through a protein hole: implications for combination of human chorionic gonadotropin subunits. Protein Sci 2001;10:226–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Celik F, Guzel AI, Kuyumcuoglu U, Celik Y. Dietary antioxidant levels in hyperemesis gravidarum: a case control study. Ginekol Pol 2011;82:840–4. [PubMed] [Google Scholar]
- 43.Zhang Y, Cantor RM, MacGibbon K,. et al. Familial aggregation of hyperemesis gravidarum. Am J Obstet Gynecol 2011;204:230 e1–7. [DOI] [PMC free article] [PubMed] [Google Scholar]


